The following year, Tulinius et al. [46] examined the effect of a single Icelandic founder BRCA2 PV (999del5) on cancer risk among families of 995 breast cancer patients in Iceland, 90 of whom tested positive for the BRCA2 founder. The gene discussed is BRCA2; the disease is cancer.